valsartan has been researched along with Renal Insufficiency, Chronic in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 15 (39.47) | 24.3611 |
| 2020's | 19 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hori, M; Imamura, T; Kinugawa, K | 1 |
| Bian, W; Cheng, H; Yang, L; Ye, N | 1 |
| Lang, H; Melk, A; Schmidt, BMW; Vollmer Barbosa, C | 1 |
| Jia, R; Jiang, L; Li, S; Raj, A; Sun, C; Sun, D; Wu, X; Xu, Y; Zhang, X; Zheng, Z | 1 |
| Alonso-Titos, J; Gaitán-Román, D; Hernández, D; Martín-Reyes, G; Martínez-Esteban, MD; Moreno-Ortiz, A; Pozo-Álvarez, R; Ruiz-Esteban, P; Vázquez-Sánchez, T | 1 |
| Agostoni, P; Cimino, R; Ferrari, C; Mantegazza, V; Mapelli, M; Maragna, R; Pepi, M; Pontone, G | 1 |
| Azushima, K; Tamura, K; Tsukamoto, S; Uehara, T; Wakui, H | 1 |
| Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Cleland, JGF; Khordoc, C; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O; Zhang, R | 1 |
| Chang, HY; Yin, WH | 1 |
| Hryniewiecki, T; Kodziszewska, K; Kruszewski, M; Leszek, P; Pączek, L; Śmigielski, W; Sochanowicz, B | 1 |
| Ding, Z; Li, Y; Liu, R; Wang, Q; Zang, Y; Zhang, G; Zhang, X | 1 |
| Huh, W; Jang, HR; Jeon, J; Kim, DH; Kim, DJ; Kim, HY; Kim, YG; Lee, JE | 1 |
| Claessen, B; Mehran, R; Nicolas, J | 1 |
| Chen, G; Deng, Z; Fang, Y; Kang, H; Qin, G; Wang, K; Zhang, J; Zhang, X | 1 |
| Haynes, R; Judge, PK | 1 |
| Ferreira, JP; McCausland, FR; Packer, M; Patel, RB; Rossignol, P; Shah, SJ; Solomon, SD; Stockbridge, N; Ter Maaten, JM; Thompson, A; Vaduganathan, M; Zannad, F | 1 |
| Cui, X; Han, D; He, W; Jin, Z; Liu, Z; Raphael, DM; Shangguan, J; Shen, D | 1 |
| Daly, S; McGrath, A; O'Connor, E; Petch, S | 1 |
| Alonso Salinas, GL; Bascompte Claret, R; Cordero Pereda, D; Del Prado Díaz, S; Gayán Ordás, J; Jiménez-Blanco Bravo, M; Morillas Climent, H; Seller Moya, J; Valle, A; Zamorano Gómez, JL | 1 |
| Gaikwad, AB; Malek, V | 1 |
| Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S | 1 |
| James, M; Manns, B | 1 |
| Antonio, ZL; Glazer, RD; Kang, HG; Lou-Meda, R; Stiller, B; Tan, M; Valentin, MA; Wang, L; Yap, HK; Zielinska, E | 1 |
| Chang, HC; Chang, HY; Chen, CN; Chong, E; Feng, AN; Fong, MC; Hsueh, CW; Huang, KC; Lai, WT; Yin, WH | 1 |
| Cohn, JN; Gimpelewicz, C; Hua, TA; Kandra, A; Krum, H; Latini, R; Lesogor, A; Massie, B; Tognoni, G; Zalewski, A | 1 |
| Bobkova, IN; Chebotareva, NV; Kozlovskaia, LV; Li, OA; Nanchikeeva, ML; Plieva, OK | 1 |
| Izumikawa, Y; Kato, H; Kojima, K; Kubo, E; Nagura, M; Nosaka, H; Shima, T; Shimada, M; Shiraishi, T; Tanemoto, M; Tomioka, S; Uchida, S; Ueda, S; Yano, H | 1 |
| Ecder, T | 1 |
| Kimura, K; Shibagaki, Y; Uehara, K; Yasuda, T | 1 |
| Lin, JX; Lin, LM; Wu, MF; Wu, Y | 1 |
| Ameer, OZ; Avolio, AP; Butlin, M; Kaschina, E; Phillips, JK; Sommerfeld, M | 1 |
| Fukuda, M | 1 |
| Ichihara, A; Itoh, H; Kaneshiro, Y; Kinouchi, K; Kurauchi-Mito, A; Sakoda, M | 1 |
| Derbentseva, EA; Dralova, OV; Ermolaeva, AS; Maksimov, ML; Starodubtsev, AK | 1 |
| Endoh, M; Ideura, T; Kamata, K; Kimura, K; Suzuki, D; Tamura, K; Toya, Y; Umemura, S; Yasuda, T; Yoshimura, A | 1 |
| Akashiba, A; Ando, N; Inada, H; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Ohta, S; Ono, H; Takahashi, T; Tsukada, K; Yoshii, M | 1 |
| Ikeda, N; Inoue, T; Komiyama, N; Kyo, S; Matsumoto, K; Nishimura, S; Suzuki, H | 1 |
11 review(s) available for valsartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Stroke Volume; Valsartan | 2022 |
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Humans; Hyperkalemia; Neprilysin; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Valsartan | 2022 |
Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Kidney; Neprilysin; Receptors, Angiotensin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Implications of Kidney Disease in the Cardiac Patient.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Contrast Media; Drug Combinations; Factor Xa Inhibitors; Female; Humans; Male; Percutaneous Coronary Intervention; Prevalence; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Tetrazoles; Valsartan | 2020 |
Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Stroke Volume; Treatment Outcome; Valsartan | 2020 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Valsartan | 2021 |
Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
Topics: Aminobutyrates; Animals; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Humans; Neprilysin; Renal Insufficiency, Chronic; Tetrazoles; Valsartan | 2017 |
[Neprilysin inhibition and chronic kidney disease].
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Renal and metabolic effects of valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Humans; Protective Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2014 |
Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Contraindications; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, Chronic; Tetrazoles; Valsartan | 2016 |
8 trial(s) available for valsartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Child; Cough; Creatinine; Drug Therapy, Combination; Female; Fever; Glomerular Filtration Rate; Headache; Humans; Hypertension; Male; Nasopharyngitis; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Serum Albumin, Human; Severity of Illness Index; Time Factors; Treatment Outcome; Valsartan | 2019 |
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Estimated Glomerular Filtration Rate Variability Independently Predicts Renal Prognosis in Advanced Chronic Kidney Disease Patients.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proteinuria; Renal Insufficiency, Chronic; Reproducibility of Results; Sex Factors; Valsartan | 2015 |
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Epidemiologic Research Design; Female; Glomerular Filtration Rate; Humans; Irbesartan; Kidney; Male; Middle Aged; Pilot Projects; Renal Insufficiency, Chronic; Single-Blind Method; Tetrazoles; United Kingdom; Valsartan | 2017 |
Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Carotid Arteries; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Tetrazoles; Thiazides; Valine; Valsartan | 2009 |
Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Comorbidity; Creatinine; Disease Progression; Female; Humans; Hypertension; Japan; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Renal Replacement Therapy; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Female; Glomerulonephritis; Humans; Middle Aged; Nephrosclerosis; Proteinuria; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2005 |
Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Patient Selection; Protective Agents; Renal Artery Obstruction; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2006 |
19 other study(ies) available for valsartan and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Japan; Male; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Creatinine; Drug Combinations; Heart Failure; Humans; Kidney; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i.
Topics: Female; Heart Failure; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Glucose; Heart Failure; Hospitalization; Humans; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Stroke Volume; United States; Valsartan | 2023 |
Response to "Grey Areas and Open Questions in Neprilysin Inhibition".
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Grey areas and open questions in neprilysin inhibition.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.
Topics: Animals; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Renal Insufficiency, Chronic; Signal Transduction; Silybin; Transforming Growth Factor beta1; Valsartan | 2020 |
Urinary angiotensinogen as a surrogate marker predicting the antiproteinuric effects of angiotensin receptor blockers in patients with overt proteinuria: a multicenter prospective study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Female; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Treatment Outcome; Valsartan | 2020 |
Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Coronary Disease; Drug Combinations; Echocardiography; Heart Failure; Humans; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Valsartan exposure in pregnancy with resultant anhydramnios and chronic kidney disease in a late preterm infant.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Oligohydramnios; Pregnancy; Renal Insufficiency, Chronic; Valsartan; Young Adult | 2021 |
Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Systolic; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Spain; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Humans; Irbesartan; Neprilysin; Renal Insufficiency, Chronic; Risk Factors; Tetrazoles; Valsartan | 2018 |
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
[General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection].
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiotonic Agents; Fibrosis; Humans; Kidney; Myocardium; Myofibroblasts; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2013 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Drug Costs; Drug Substitution; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Nephrology; Patient Satisfaction; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Retrospective Studies; Surveys and Questionnaires; Telmisartan; Tetrazoles; Valsartan | 2015 |
Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction, and Structural Remodeling in a Rat Model of Chronic Kidney Disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Blood Pressure; Cathepsin D; Cathepsin L; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hypertension; Kidney; Male; Matrix Metalloproteinase 9; NF-kappa B; Polycystic Kidney Diseases; Rats, Inbred Lew; Renal Insufficiency, Chronic; Time Factors; Valsartan; Vascular Remodeling; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2016 |
Can changing antihypertensive administration time alone reduce the risk for CVD in nondipper patients with CKD?
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chronotherapy; Follow-Up Studies; Humans; Hypertension; Incidence; Renal Insufficiency, Chronic; Risk Assessment; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2008 |
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Enalapril; Female; Fumarates; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |